By Josh White
Date: Wednesday 10 Apr 2024
(Sharecast News) - 4basebio confirmed the provision of its synthetic DNA to an unnamed tier-one pharmaceutical company on Wednesday.
By Josh White
Date: Thursday 21 Mar 2024
(Sharecast News) - Synthetic DNA product developer 4basebio announced on Thursday that its client, Helix Nanotechnologies, has achieved a significant milestone with the receipt of HREC approval in Australia.
By Josh White
Date: Friday 01 Mar 2024
(Sharecast News) - 4basebio announced a significant contract through a competitive tender process on Friday, to provide research and GMP-grade synthetic DNA for the advancement of RNA therapeutics and vaccines at CPI's RNA Centre of Excellence.
Currency | UK Pounds |
Share Price | 1,028.00p |
Change Today | -7.00p |
% Change | -0.68 % |
52 Week High | 1,070.00 |
52 Week Low | 500.00 |
Volume | 0 |
Shares Issued | 12.81m |
Market Cap | £131.64m |
Value |
---|
Price Trend |
---|
Income |
---|
Growth |
---|
No dividends found |
You are here: research